ABC | Volume 114, Nº2, Fevereiro 2020

Atualização Atualização da Diretriz Brasileira de Cardiologia Nuclear – 2020 Arq Bras Cardiol. 2020; 114(2):325-429 445. Bhogal S, Ladia V, Sitwala P, Cook E, Bajaj K, Ramu V, et al. Cardiac amyloidosis: An updated review with emphasis on diagnosis and future directions. Curr Probl Cardiol. 2018;43(1):10-34. 446. Carroll JD, Gaasch WH, McAdam KP. Amyloid cardiomyopathy: characterization by a distinctive voltage/mass relation. Am J Cardiol. 1982;49(1):9-13. 447. Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404-12. 448. Glaudemans AW, van Rheenen RW, van den Berg MP, Noordzij W, Koole M, Blokzijl H, et al. Bone scintigraphy with (99m) technetium- hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin derived systemic amyloidosis. Amyloid. 2014;21(1):35-44. 449. Bokhari S, Castaño A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. 99mTc- PYP Scintigraphy for Cardiac Amyloidosis Circ Cardiovasc Imaging. 2013;6(2):195-201. 450. Van Der Gucht A, Galat A, Rosso J, Guellich A, Garot J, Bodez D, et al. [18F]- NaFPET/CTimagingincardiacamyloidosis.JNuclCardiol.2016;23(4):846-9. 451. Gagliardi C, Tabacchi E, Bonfiglioli R, Diodato S, Nanni C, Guidalotti P, et al. Does the etiology of cardiac amyloidosis determine the myocardial uptake of [18F]-NaF PET/CT? J Nucl Cardiol. 2017;24(2):746-9. 452. Trivieri MG, DweckMR, Abgral R, Robson PM, Karakatsanis NA, Lala A, et al. 18F-sodium fluoride PET/MR for the assessment of cardiac amyloidosis. J Am Coll Cardiol. 2016;68(24):2712-4. 453. Kung J, Zhuang H, Yu JQ, Duarte PS, Alavi A. Intense fluorodeoxyglucose activity in pulmonary amyloid lesions on positron emission tomography. Clin Nucl Med. 2003;28(12):975-6. 454. Mekinian A, Jaccard A, Soussan M, Launay D, Berthier S, Federici L, et al; Centre de Référence des Amyloses immunoglobulinémiques et autres maladies liées aux dépots des immunoglobulinesmonoclonales. 18F-FDG PET/CT in patients with amyloid light-chain amyloidosis: case series and literature review. Amyloid. 2012;19(2):94-98. 455. Lee SP, Lee ES, Choi H, Im HJ, Koh Y, Lee MH, et al. 11C-Pittsburgh B PET imagingincardiacamyloidosis.JACCCardiovascImaging.2015;8(1):50-59. 456. Pilebro B, Arvidsson S, Lindqvist P, Sundström T, Westermark P, Antoni G, et al. Positron emission tomography (PET) utilizing Pittsburgh compound B (PIB) for detection of amyloid heart deposits in hereditary transthyretin amyloidosis (ATTR). J Nucl Cardiol. 2018;25(1):240-8. 457. Dorbala S, Vangala D, Semer J, Strader C, Bruyere JR Jr, Di Carli MF, et al. Imaging cardiac amyloidosis: a pilot study using 18F-florbetapir positron emission tomography. Eur J Nucl MedMol Imaging. 2014;41(9):1652-62. 458. Osborne DR, Acuff SN, Stuckey A, Wall JS. A routine PET/CT protocol with streamlined calculations for assessing cardiac amyloidosis using (18) F-florbetapir. Front Cardiovasc Med. 2015 May;2:23. 459. LawWP,WangWY,MoorePT,MolleePN,NgAC.Cardiacamyloid imaging with 18F-florbetaben PET: a pilot study. J Nucl Med. 2016;57(11):1733-9. 460. Lee SP, Lee ES, Choi H, Im HJ, Koh Y, Lee MH, et al. 11C-Pittsburgh B PET imaging incardiacamyloidosis.JACCCardiovascImaging.2015;8(1):50-9. Este é um artigo de acesso aberto distribuído sob os termos da licença de atribuição pelo Creative Commons 429